Reading size

PACK IN HAND · ONE-PAGE CHECK

Medicine pack check sheet

Print this sheet or fill it in before speaking with a pharmacist or clinician. Copy only what is printed on the pack in hand. The published fields below are starting points from this record, not proof that your pack is the same product.

Published record starting point

Record display name
YAZ
Generic name / active ingredient
drospirenone and ethinyl estradiol
Dosage-form class
Dosage form and presentation as documented in the linked primary label
Route
Oral
Record reviewed
2026-09-04

Copy from the pack in hand

Source-linked reading points

  • Each light-pink active tablet contains drospirenone 3 mg and ethinyl estradiol 0.02 mg; the white tablets are inert. The 3 and 0.02 figures are not added into one comparable strength, and 24, 4, 28 and three blisters are not an individual's tablet count.
  • The boxed warning states that women over 35 who smoke should not use YAZ and that smoking increases serious cardiovascular-event risk with combined oral contraceptives. Chest pain, breathing difficulty, one-sided leg swelling or pain, sudden neurologic symptoms or another acute serious concern requires immediate local emergency help, not a web decision.
  • Drospirenone has antimineralocorticoid activity. Adrenal, kidney or liver problems, or co-listing potassium, potassium-sparing diuretics, spironolactone, an ACE inhibitor, ARB, aldosterone antagonist, heparin or long-term daily NSAID use requires priority review of potassium and the complete medicine list. The page does not create a stop or separation plan.
  • YASMIN, BEYAZ, SAFYRAL, SLYND and other 21+7 or 24+4 products can differ in ingredients, oestrogen, folate, active-tablet count or label. Brand, colour, tablet count or shared drospirenone does not permit self-substitution, assembly or alternation.

Reviewed presentation examples — compare every field

  • Each blister has 24 light-pink active tablets (drospirenone 3 mg / ethinyl estradiol 0.02 mg per tablet) plus 4 white inert tablets; three blisters per outer packNDC 50419-405-03

EDITORIAL RECORD

Who prepared and checked this page

Byline
OriginDrug Content Editorial
Review role
Public primary-source verification
Last reviewed
2026-09-04
Source record
3 clickable primary-source entry points are listed with this dossier.

The review role checks source traceability, stated market, document version and product-identity fields. It is not a claim of clinical licensure, prescribing authority or individual pharmacy service. Read the editorial policy.

Search records
Enlarged public-label image